– ORGS is an overlooked subcontracted manufacturing company for biotech drug developers, already with major companies as partners, like CRISPR (CRSP) and Adaptimmune (ADAP) among others
– A similar company is valued at 1.5X ORGS’ current stock price based on almost the same revenue figures last year, suggesting immediate upside potential of 50% or more for ORGS. Revenue has been growing consistently for the last few years, and the market for cell therapies – and manufacturing solutions – is huge; the company could be worth 5x or more with great execution in the coming years.
Public social media companies have been hit or miss as investments. Facebook’s (NASDAQ: FB) presence in our day-to-day lives has only increased in the last few years, and the stock has been a meteoric winner. Others, like Snapchat (SNAP), have, at least for now, …View the full post at: Social Media or Biotech? This Overlooked Stock Has 50% Of Upside Potential Immediately …